Company Encyclopedia
View More

Q32 Bio
QTTB.US
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
1.880 T
QTTB.USMarket value -Rank by Market Cap -/-
Valuation analysis

P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
- P/E
- Price
- High
- Median
- Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
- P/B
- Price
- High
- Median
- Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
- P/S
- Price
- High
- Median
- Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
- Dividend Yield
- Price
- High
- Median
- Low
Institutional View & Shareholder
Analyst Ratings
- Price--
- Highest--
- Lowest--
News
View More

